Eco Animal Health Group PLC EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN(R) (2948R)
June 29 2020 - 1:00AM
UK Regulatory
TIDMEAH
RNS Number : 2948R
Eco Animal Health Group PLC
29 June 2020
ECO Animal Health Group plc
("ECO" or the "Group")
(AIM: EAH)
EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN(R) IN PIGS
ECO Animal Health Group plc (the "Group") is pleased to announce
that, as anticipated, a marketing authorisation has been received
from the European Medicines Agency (EMA) for the use of Aivlosin(R)
625 mg/g Water Soluble Granules (WSG) for the treatment and
metaphylaxis (disease control) of Mycoplasma hyopneumoniae in
pigs.
The Group had previously announced a positive opinion on 22(nd)
May 2020 with the marketing authorisation expected within two
months.
Mycoplasma hyopneumoniae is the most common primary pathogen in
pig respiratory disease and is a key instigator of secondary
bacterial and viral pathogens. The EU market accounts for
approximately 15 per cent of the world's swine market.
Aivlosin(R), ECO's patented antimicrobial, is used under
veterinary prescription for the treatment of a variety of
economically important respiratory and enteric (gut) diseases in
poultry and pigs.
Marc Loomes, CEO, commented: "We are very pleased that this
marketing authorisation has been received after only one month and
we look forward to offering Aivlosin(R) for the treatment of
Mycoplasma infections in this important market. This further
approval underlines the value of Aivlosin(R) for the safe and
highly effective treatment of a range of diseases and
infections."
Contacts:
ECO Animal Health Group plc
Marc Loomes (CEO)
Christopher Wilks (CFO) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
N+1 Singer (Nominated Adviser & Joint
Broker)
Mark Taylor
Peter Steel
Alex Bond 020 7496 3000
Peel Hunt LLP (Joint Broker)
James Steel
Dr Christopher Golden 020 7418 8900
ECO Animal Health Group plc ("ECO" or "the "GROUP") researches,
develops and commercialises products for livestock. Our business
strategy is to generate shareholder value by achieving the maximum
sales potential from the existing product portfolio whilst
investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBIGDLDUDDGGI
(END) Dow Jones Newswires
June 29, 2020 02:00 ET (06:00 GMT)
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Apr 2024 to May 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From May 2023 to May 2024